A prospective study of G-CSF-primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children

A Pediatric Blood and Marrow Transplant Consortium (PBMTC) study

Haydar Frangoul, Eneida R. Nemecek, David D Billheimer, Michael A. Pulsipher, Shakila Khan, Ann Woolfrey, Becky Manes, Catherine Cole, Mark C. Walters, Mouhab Ayas, Yaddanapudi Ravindranath, John E. Levine, Stephan A. Grupp

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

A prospective multicenter trial was conducted to evaluate the safety and feasibility of granulocyte colony-stimulating factor (G-CSF)-primed bone marrow (G-BM) in children receiving allogeneic bone marrow transplantation (BMT). A total of 42 children with a median age of 9.8 years (range, 0.8-17 years) were enrolled. Donors with median age of 9.2 years (range, 1.1-22 years) received 5 μg/kg per day of subcutaneous G-CSF for 5 consecutive days. BM was harvested on the fifth day. No donor experienced complications related to G-CSF administration or marrow harvest. Median nucleated (NC) and CD34 cells infused was 6.7 × 108/kg (range, 2.4-18.5 × 108/kg) and 7.4 × 106/kg (range, 2-27.6 × 106/kg), respectively. Neutrophil and platelet engraftment was at a median of 19 days (range, 13-28 days) and 20 days (range, 9-44 days), respectively. A total of 13 (32%) patients developed grade 2 graft-versus-host disease (GVHD), and 5 (13%) of 40 evaluable patients developed chronic GVHD (3 limited and 2 extensive). Higher cell dose was not associated with increased risk of acute or chronic GVHD. Overall survival and event-free survival at 2 years were 81% and 69%, respectively. Collection of G-BM from pediatric donors is safe, and can result in high NC and CD34 cell doses that facilitate engraftment after myeloablative BMT without a discernable increase in the risk of GVHD.

Original languageEnglish (US)
Pages (from-to)4584-4587
Number of pages4
JournalBlood
Volume110
Issue number13
DOIs
StatePublished - Dec 15 2007
Externally publishedYes

Fingerprint

Transplantation (surgical)
Transplants
Pediatrics
Homologous Transplantation
Graft vs Host Disease
Granulocyte Colony-Stimulating Factor
Stem cells
Bone Marrow Transplantation
Grafts
Bone
Blood
Stem Cells
Bone Marrow
Prospective Studies
Tissue Donors
Platelets
Multicenter Studies
Disease-Free Survival
Neutrophils
Blood Platelets

ASJC Scopus subject areas

  • Hematology

Cite this

A prospective study of G-CSF-primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children : A Pediatric Blood and Marrow Transplant Consortium (PBMTC) study. / Frangoul, Haydar; Nemecek, Eneida R.; Billheimer, David D; Pulsipher, Michael A.; Khan, Shakila; Woolfrey, Ann; Manes, Becky; Cole, Catherine; Walters, Mark C.; Ayas, Mouhab; Ravindranath, Yaddanapudi; Levine, John E.; Grupp, Stephan A.

In: Blood, Vol. 110, No. 13, 15.12.2007, p. 4584-4587.

Research output: Contribution to journalArticle

Frangoul, H, Nemecek, ER, Billheimer, DD, Pulsipher, MA, Khan, S, Woolfrey, A, Manes, B, Cole, C, Walters, MC, Ayas, M, Ravindranath, Y, Levine, JE & Grupp, SA 2007, 'A prospective study of G-CSF-primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children: A Pediatric Blood and Marrow Transplant Consortium (PBMTC) study', Blood, vol. 110, no. 13, pp. 4584-4587. https://doi.org/10.1182/blood-2007-07-101071
Frangoul, Haydar ; Nemecek, Eneida R. ; Billheimer, David D ; Pulsipher, Michael A. ; Khan, Shakila ; Woolfrey, Ann ; Manes, Becky ; Cole, Catherine ; Walters, Mark C. ; Ayas, Mouhab ; Ravindranath, Yaddanapudi ; Levine, John E. ; Grupp, Stephan A. / A prospective study of G-CSF-primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children : A Pediatric Blood and Marrow Transplant Consortium (PBMTC) study. In: Blood. 2007 ; Vol. 110, No. 13. pp. 4584-4587.
@article{514126be9f6e49348c1efdb3ef1c4c77,
title = "A prospective study of G-CSF-primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children: A Pediatric Blood and Marrow Transplant Consortium (PBMTC) study",
abstract = "A prospective multicenter trial was conducted to evaluate the safety and feasibility of granulocyte colony-stimulating factor (G-CSF)-primed bone marrow (G-BM) in children receiving allogeneic bone marrow transplantation (BMT). A total of 42 children with a median age of 9.8 years (range, 0.8-17 years) were enrolled. Donors with median age of 9.2 years (range, 1.1-22 years) received 5 μg/kg per day of subcutaneous G-CSF for 5 consecutive days. BM was harvested on the fifth day. No donor experienced complications related to G-CSF administration or marrow harvest. Median nucleated (NC) and CD34 cells infused was 6.7 × 108/kg (range, 2.4-18.5 × 108/kg) and 7.4 × 106/kg (range, 2-27.6 × 106/kg), respectively. Neutrophil and platelet engraftment was at a median of 19 days (range, 13-28 days) and 20 days (range, 9-44 days), respectively. A total of 13 (32{\%}) patients developed grade 2 graft-versus-host disease (GVHD), and 5 (13{\%}) of 40 evaluable patients developed chronic GVHD (3 limited and 2 extensive). Higher cell dose was not associated with increased risk of acute or chronic GVHD. Overall survival and event-free survival at 2 years were 81{\%} and 69{\%}, respectively. Collection of G-BM from pediatric donors is safe, and can result in high NC and CD34 cell doses that facilitate engraftment after myeloablative BMT without a discernable increase in the risk of GVHD.",
author = "Haydar Frangoul and Nemecek, {Eneida R.} and Billheimer, {David D} and Pulsipher, {Michael A.} and Shakila Khan and Ann Woolfrey and Becky Manes and Catherine Cole and Walters, {Mark C.} and Mouhab Ayas and Yaddanapudi Ravindranath and Levine, {John E.} and Grupp, {Stephan A.}",
year = "2007",
month = "12",
day = "15",
doi = "10.1182/blood-2007-07-101071",
language = "English (US)",
volume = "110",
pages = "4584--4587",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "13",

}

TY - JOUR

T1 - A prospective study of G-CSF-primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children

T2 - A Pediatric Blood and Marrow Transplant Consortium (PBMTC) study

AU - Frangoul, Haydar

AU - Nemecek, Eneida R.

AU - Billheimer, David D

AU - Pulsipher, Michael A.

AU - Khan, Shakila

AU - Woolfrey, Ann

AU - Manes, Becky

AU - Cole, Catherine

AU - Walters, Mark C.

AU - Ayas, Mouhab

AU - Ravindranath, Yaddanapudi

AU - Levine, John E.

AU - Grupp, Stephan A.

PY - 2007/12/15

Y1 - 2007/12/15

N2 - A prospective multicenter trial was conducted to evaluate the safety and feasibility of granulocyte colony-stimulating factor (G-CSF)-primed bone marrow (G-BM) in children receiving allogeneic bone marrow transplantation (BMT). A total of 42 children with a median age of 9.8 years (range, 0.8-17 years) were enrolled. Donors with median age of 9.2 years (range, 1.1-22 years) received 5 μg/kg per day of subcutaneous G-CSF for 5 consecutive days. BM was harvested on the fifth day. No donor experienced complications related to G-CSF administration or marrow harvest. Median nucleated (NC) and CD34 cells infused was 6.7 × 108/kg (range, 2.4-18.5 × 108/kg) and 7.4 × 106/kg (range, 2-27.6 × 106/kg), respectively. Neutrophil and platelet engraftment was at a median of 19 days (range, 13-28 days) and 20 days (range, 9-44 days), respectively. A total of 13 (32%) patients developed grade 2 graft-versus-host disease (GVHD), and 5 (13%) of 40 evaluable patients developed chronic GVHD (3 limited and 2 extensive). Higher cell dose was not associated with increased risk of acute or chronic GVHD. Overall survival and event-free survival at 2 years were 81% and 69%, respectively. Collection of G-BM from pediatric donors is safe, and can result in high NC and CD34 cell doses that facilitate engraftment after myeloablative BMT without a discernable increase in the risk of GVHD.

AB - A prospective multicenter trial was conducted to evaluate the safety and feasibility of granulocyte colony-stimulating factor (G-CSF)-primed bone marrow (G-BM) in children receiving allogeneic bone marrow transplantation (BMT). A total of 42 children with a median age of 9.8 years (range, 0.8-17 years) were enrolled. Donors with median age of 9.2 years (range, 1.1-22 years) received 5 μg/kg per day of subcutaneous G-CSF for 5 consecutive days. BM was harvested on the fifth day. No donor experienced complications related to G-CSF administration or marrow harvest. Median nucleated (NC) and CD34 cells infused was 6.7 × 108/kg (range, 2.4-18.5 × 108/kg) and 7.4 × 106/kg (range, 2-27.6 × 106/kg), respectively. Neutrophil and platelet engraftment was at a median of 19 days (range, 13-28 days) and 20 days (range, 9-44 days), respectively. A total of 13 (32%) patients developed grade 2 graft-versus-host disease (GVHD), and 5 (13%) of 40 evaluable patients developed chronic GVHD (3 limited and 2 extensive). Higher cell dose was not associated with increased risk of acute or chronic GVHD. Overall survival and event-free survival at 2 years were 81% and 69%, respectively. Collection of G-BM from pediatric donors is safe, and can result in high NC and CD34 cell doses that facilitate engraftment after myeloablative BMT without a discernable increase in the risk of GVHD.

UR - http://www.scopus.com/inward/record.url?scp=39649088491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39649088491&partnerID=8YFLogxK

U2 - 10.1182/blood-2007-07-101071

DO - 10.1182/blood-2007-07-101071

M3 - Article

VL - 110

SP - 4584

EP - 4587

JO - Blood

JF - Blood

SN - 0006-4971

IS - 13

ER -